共 8 条
[3]
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
[J].
ARTHRITIS AND RHEUMATISM,
2006, 54 (09)
:2793-2806
[4]
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis
[J].
ARTHRITIS AND RHEUMATISM,
2007, 56 (12)
:3896-3908